We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+43.89%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$2.32B
AUM Growth
+$601M
Cap. Flow
+$106M
Cap. Flow %
4.57%
Top 10 Hldgs %
72.02%
Holding
31
New
6
Increased
4
Reduced
7
Closed
2

Top Buys

Rank Stock Value
1
SAGE
Sage Therapeutics
SAGE
+$55.6M
2
DTIL icon
Precision BioSciences
DTIL
+$32.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$30.6M
4
IFRX icon
InflaRx
IFRX
+$27M
5
ALEC icon
Alector
ALEC
+$18.9M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$43.1M
2
ARVN icon
Arvinas
ARVN
+$17.7M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$17.1M
4
ASND icon
Ascendis Pharma A/S
ASND
+$9.47M
5
MYOV
Myovant Sciences Ltd.
MYOV
+$3.42M

Sector Composition

Rank Sector Weight
1 Healthcare 98.45%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALEC icon
26
Alector
ALEC
$169M
$18.7M 0.81%
+1,000,000
New +$18.9M
SWAV
27
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$16.6M 0.72%
+495,608
New +$16.5M
SCPH
28
DELISTED
scPharmaceuticals
SCPH
$8.57M 0.37%
2,857,143
– –
GTHX
29
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$6.03M 0.26%
+363,051
New +$6.89M
TARA icon
30
Protara Therapeutics
TARA
$214M
– –
-33,437
Closed -$3.04M
IMMU
31
DELISTED
Immunomedics Inc
IMMU
– –
-3,021,466
Closed -$43.1M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, RA Capital Management held 31 positions worth $2.32B, up 35% from $1.72B the previous quarter. Its ten largest holdings account for 72% of the portfolio.

RA Capital Management deployed $106M of net new capital in Q1 2019, opening 6 new positions and adding to 4 existing holdings. Its largest new stake was Sage Therapeutics: 384,001 shares worth $61.1M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 96% a quarter earlier.

On the sell side, the largest reduction was Arvinas, an estimated $17.7M trimmed.

  • RA Capital Management's largest Q1 2019 buy was Sage Therapeutics: 384,001 shares worth $61.1M.
  • RA Capital Management added most to InflaRx in Q1 2019, an estimated $27M increase.
  • RA Capital Management's biggest Q1 2019 reduction was Arvinas, cutting an estimated $17.7M.
  • RA Capital Management fully exited Immunomedics Inc in Q1 2019, selling an estimated $43.1M.
  • RA Capital Management's ten largest holdings make up 72% of its $2.32B portfolio in Q1 2019.
  • RA Capital Management opened 6 new positions and closed 2 in Q1 2019.
  • RA Capital Management's portfolio value rose 35% quarter-over-quarter to $2.32B.

Based on RA Capital Management's 13F filing for Q1 2019, filed 15 May 2019.